Related Experiment Video

Updated: Jun 21, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

17.9K

Preclinical Therapeutic Efficacy of RAF/MEK/ERK and IGF1R/AKT/mTOR Inhibition in Neuroblastoma

Stacey Stauffer1, Jacob S Roth2, Edjay R Hernandez3

  • 1Laboratory of Cell and Developmental Signaling, Center for Cancer Research, National Cancer Institute, NIH, 8560 Progress Drive, Frederick, MD 21701, USA.

Cancers
|July 13, 2024
PubMed

Insights

Combining trametinib and ganitumab showed preclinical synergy against RAS-mutated neuroblastoma by suppressing proliferation and inducing apoptosis. Further research is needed before clinical trials for this targeted therapy combination.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Activating RAS/MAPK pathway mutations are common in relapsed neuroblastoma.
  • MEK inhibitors show promise but lack durable responses as monotherapy.
  • Combination therapies are needed for RAS-mutated neuroblastoma.

Purpose of the Study:

  • To investigate the synergistic efficacy of combining trametinib (MEK inhibitor) and ganitumab (IGF1R antibody) in RAS-mutated neuroblastoma.
  • To evaluate the combination's effect on neuroblastoma cell proliferation, apoptosis, and tumor growth in preclinical models.

Main Methods:

  • In vitro cell culture studies assessing proliferation and apoptosis.
  • In vivo xenograft models (heterotopic and orthotopic) to evaluate tumor initiation, growth, and survival.
  • Combination therapy with trametinib and ganitumab.

Main Results:

  • Trametinib and ganitumab demonstrated synergistic suppression of neuroblastoma cell proliferation and induced apoptosis in vitro.
  • The combination therapy delayed tumor initiation and prolonged survival in xenograft models.
  • Primary and metastatic tumor growth was still observed despite combination treatment.

Conclusions:

  • The combination of trametinib and ganitumab shows preclinical therapeutic potential for RAS-mutated neuroblastoma.
  • Further preclinical investigation is required to optimize this combination for clinical application.
  • This combination warrants further study for relapsed or refractory RAS-mutated neuroblastoma.
Keywords:
IGF1RMEKRASneuroblastoma

More Related Videos

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.0K
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.7K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K